Open AccessThe breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Author(s) -
Tan Su Yin Elaine,
Hu Yong Xian,
Huang He
Publication year - 2022
Publication title -
immunomedicine
Language(s) - English
Resource type - Journals
ISSN - 2510-5345
DOI - 10.1002/imed.1039
Subject(s) - chimeric antigen receptor , medicine , cd20 , lymphoma , cd19 , food and drug administration , cell therapy , antigen , oncology , immunology , cancer research , t cell , cell , pharmacology , immune system , biology , genetics
Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment option for relapsed or refractory non‐Hodgkin lymphoma (NHL). CD20 CAR T‐cell infusion has achieved remarkable clinical outcomes in patients with B‐cell malignancies. This review will cover the current situations, advantages, limitations, prospects, and application of CD20 CAR T‐cell therapy.